- Home
- SLN vs ODV Comparison
SLN vs ODV Comparison
Compare SLN & ODV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLN
- ODV
- Stock Information
- Founded
- SLN 1994
- ODV 2005
- Country
- SLN United Kingdom
- ODV Canada
- Employees
- SLN N/A
- ODV N/A
- Industry
- SLN Biotechnology: Pharmaceutical Preparations
- ODV Precious Metals
- Sector
- SLN Health Care
- ODV Basic Materials
- Exchange
- SLN Nasdaq
- ODV Nasdaq
- Market Cap
- SLN 273.9M
- ODV 302.0M
- IPO Year
- SLN N/A
- ODV N/A
- Fundamental
- Price
- SLN $6.11
- ODV $2.44
- Analyst Decision
- SLN Buy
- ODV
- Analyst Count
- SLN 5
- ODV 0
- Target Price
- SLN $32.60
- ODV N/A
- AVG Volume (30 Days)
- SLN 105.4K
- ODV 595.1K
- Earning Date
- SLN 08-14-2025
- ODV 08-11-2025
- Dividend Yield
- SLN N/A
- ODV N/A
- EPS Growth
- SLN N/A
- ODV N/A
- EPS
- SLN N/A
- ODV N/A
- Revenue
- SLN $27,701,000.00
- ODV $1,943,159.00
- Revenue This Year
- SLN N/A
- ODV $539.98
- Revenue Next Year
- SLN N/A
- ODV $397.65
- P/E Ratio
- SLN N/A
- ODV N/A
- Revenue Growth
- SLN N/A
- ODV N/A
- 52 Week Low
- SLN $1.97
- ODV $1.16
- 52 Week High
- SLN $22.47
- ODV $2.75
- Technical
- Relative Strength Index (RSI)
- SLN 55.70
- ODV 60.16
- Support Level
- SLN $6.10
- ODV $2.46
- Resistance Level
- SLN $6.67
- ODV $2.70
- Average True Range (ATR)
- SLN 0.39
- ODV 0.13
- MACD
- SLN -0.02
- ODV 0.02
- Stochastic Oscillator
- SLN 59.70
- ODV 58.87
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
About ODV Osisko Development Corp.
Osisko Development Corp is a mineral exploration and development company engaged in the acquisition, exploration, and development of precious metals resource properties in North America. The company is focused on exploring and developing its mining assets, including the Cariboo Gold Project in British Columbia, the San Antonio gold project in Mexico, and the Trixie test mine in the USA. The Company manages its business through the exploration, evaluation, and development activities of its projects.